Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kosuke Egami"'
Autor:
Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, Atsushi Hirano, Hideki Kazuno, Satoshi Yamashita, Kosuke Egami, Yoshihiro Shibata, Ikuo Yamamiya, Fumiaki Yamashita, Yasuo Kodama, Kaoru Funabashi, Hiromi Kazuno, Toshiharu Komori, Satoshi Suzuki, Hiroshi Sootome, Hiroshi Hirai, Takeshi Sagara
Publikováno v:
ACS Medicinal Chemistry Letters. 14:396-404
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::270fb283ac492b9da7e9ad16d06a308b
https://doi.org/10.1021/acsmedchemlett.3c00006
https://doi.org/10.1021/acsmedchemlett.3c00006
Autor:
Kazuhiko Yonekura, Kazuto Nishio, Yoshimitsu Suda, Hideki Kazuno, Kosuke Egami, Takashi Suefuji, Akihiro Hashimoto, Satoko Ito, Takamasa Suzuki, Toru Takenaka, Yoshimi Aoyagi, Kimihiro Ito, Jinhong Huang, Hiroaki Ochiiwa, Yayoi Fujioka, Masanori Kato, Kazutaka Miyadera, Hidenori Fujita
VEGF receptor (VEGFR) signaling plays a key role in tumor angiogenesis. Although some VEGFR signal-targeted drugs have been approved for clinical use, their utility is limited by associated toxicities or resistance to such therapy. To overcome these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d59bff754e7c2d91aac6e32fcdab86b
https://doi.org/10.1158/1535-7163.c.6535644.v1
https://doi.org/10.1158/1535-7163.c.6535644.v1
Publikováno v:
The Proceedings of the Materials and Mechanics Conference. 2021:OS1810
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a50e5610815ffdb578b1968707ef2705
https://doi.org/10.1299/jsmemm.2021.os1810
https://doi.org/10.1299/jsmemm.2021.os1810
Autor:
Jinhong Huang, Kimihiro Ito, Yoshimi Aoyagi, Yayoi Fujioka, Kazuhiko Yonekura, Akihiro Hashimoto, Hideki Kazuno, Hidenori Fujita, Masanori Kato, Satoko Ito, Yoshimitsu Suda, Hiroaki Ochiiwa, Kazutaka Miyadera, Takamasa Suzuki, Takashi Suefuji, Kosuke Egami, Toru Takenaka, Kazuto Nishio
Publikováno v:
Molecular Cancer Therapeutics. 12:2685-2696
VEGF receptor (VEGFR) signaling plays a key role in tumor angiogenesis. Although some VEGFR signal-targeted drugs have been approved for clinical use, their utility is limited by associated toxicities or resistance to such therapy. To overcome these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3523d0f062e3dc415c8e5c98b9a32f4
https://doi.org/10.1158/1535-7163.mct-13-0459
https://doi.org/10.1158/1535-7163.mct-13-0459
Publikováno v:
The Journal of The Institute of Electrical Engineers of Japan. 126:447-450
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::575eed1076fe3ea6ce5e003138f1b7d9
https://doi.org/10.1541/ieejjournal.126.447
https://doi.org/10.1541/ieejjournal.126.447
Autor:
Kazutaka Miyadera, Ayako Sato, Akihiro Hashimoto, Masanori Kato, Hiroaki Ochiiwa, Kimihiro Ito, Kazuhiko Yonekura, Hidenori Fujita, Yayoi Fujioka, Yoshimi Aoyagi, Hideki Kazuno, Jinhong Huang, Takamasa Suzuki, Yoshimitsu Suda, Satoko Ito, Kosuke Egami, Takashi Suefuji, Toru Takenaka
Publikováno v:
Molecular Cancer Therapeutics. 10:A245-A245
The inhibition of VEGF/VEGFR has been established notable achievement as standard therapy for several cancers. However, unexpectedly success of VEGFR inhibitors (VEGFRI) has been concurrently associated with emerging new type toxicities which result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b0bffd2f3e48e128a82970884267fb4
https://doi.org/10.1158/1535-7163.targ-11-a245
https://doi.org/10.1158/1535-7163.targ-11-a245